IKT Earnings

Quarterly EPS
$-0.65
Q3 2024
$-0.17
Q4 2024
$-0.15
Q1 2025
$-0.11
Q2 2025
$-0.13
Q3 2025
$-0.10
Q4 2025
$-0.10
Q1 2026
$-0.11
Q2 2026
Latest RevenueN/A
Latest Net Income-19591231
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q2 2026-$0.110-19591231+0.0%
Q1 2026-$0.100-16380840+33.3%
Q4 2025-$0.100-12734651+41.2%
Q3 2025-$0.130-11930280+80.0%
Q2 2025-$0.110-9915523+83.3%
Q1 2025-$0.150-13678735+79.5%
Q4 2024-$0.170-12132577-100.0%+66.7%
Q3 2024-$0.650-5778066-100.0%+13.3%
Q2 2024-$0.660-4958832
Q1 2024-$0.730-4649635
Q4 2023-$0.511-4177940
Q3 2023-$0.7579.6K-4595199
Inhibikase Therapeutics (IKT) — Earnings